Integrin beta1 silencing in osteoblasts alters substrate-dependent responses to 1,25-dihydroxy vitamin D3.
Surface microroughness increases osteoblast differentiation and enhances responses of osteoblasts to 1,25-dihydroxyvitamin D3 [1alpha,25(OH)2D3]. The observations that beta1 integrin expression is increased in osteoblasts grown on Ti substrates with rough microarchitecture, and that it is regulated by 1alpha,25(OH)2D3 in a surface-dependent manner, suggest that beta1 may play a role in mediating osteoblast response. To test this hypothesis, we silenced beta1 expression in MG63 human osteoblast-like cells using small interfering RNA (siRNA) and examined the responses of the beta1-silenced osteoblasts to surface microtopography and 1alpha,25(OH)2D3. To better understand the role of beta1, MG63 cells were also treated with two different monoclonal antibodies to human beta1 to block ligand binding. beta1-silenced MG63 cells grown on a tissue culture plastic had reduced alkaline phosphatase activity and levels of osteocalcin, transforming growth factor beta1, prostaglandin E2, and osteoprotegerin in comparison with control cells. Moreover, beta1-silencing inhibited the effects of surface roughness on these parameters and partially inhibited effects of 1alpha,25(OH)2D3. Anti beta1 antibody AIIB2 had no significant effect on cell number and osteocalcin, but decreased alkaline phosphatase; MAB2253Z caused dose-dependent decreases in cell number and alkaline phosphatase and an increase in osteocalcin. Effects of 1alpha,25(OH)2D3 on cell number and alkaline phosphatase were reduced and effects on osteocalcin were increased. These findings indicate that beta1 plays a major and complex role in osteoblastic differentiation modulated by either surface microarchitecture or 1alpha,25(OH)2D3. The results also show that beta1 mediates, in part, the synergistic effects of surface roughness and 1alpha,25(OH)2D3.
Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, 315 Ferst Drive NW, Georgia 30332, USA.
Liping
L
Wang
Ge
G
Zhao
Rene
R
Olivares-Navarrete
Bryan F
BF
Bell
Marco
M
Wieland
David L
DL
Cochran
Zvi
Z
Schwartz
Barbara D
BD
Boyan
D000818:Animals; D000906:Antibodies / Q000378:metabolism; D050071:Bone Density Conservation Agents / Q000378:metabolism*; D002117:Calcitriol / Q000378:metabolism*; D018929:Cell Culture Techniques; D002460:Cell Line; D015232:Dinoprostone / Q000235:genetics / Q000378:metabolism; D020868:Gene Silencing; D006801:Humans; D019012:Integrin beta1 / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D010006:Osteoblasts / Q000166:cytology / Q000502:physiology*; D053244:Osteoprotegerin / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000378:metabolism; D013499:Surface Properties; D014025:Titanium / Q000378:metabolism; D053773:Transforming Growth Factor beta1 / Q000235:genetics / Q000378:metabolism
D000906:Antibodies; D050071:Bone Density Conservation Agents; D019012:Integrin beta1; D053244:Osteoprotegerin; D034741:RNA, Small Interfering; D053773:Transforming Growth Factor beta1; D014025:Titanium; D002117:Calcitriol; D015232:Dinoprostone